Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
Brigatinib demonstrated clinically meaningful systemic and intracranial efficacy in patients with ALK TKI-naive ALK+ NSCLC. Safety results were consistent with the known profile for brigatinib.
Authors
- Ki Hyeong Lee (ORCID: https://orcid.org/0000-0002-7830-5950)
- Maximilian J. Hochmair (ORCID: https://orcid.org/0000-0002-8673-2450)
- Masashi Kondo (ORCID: https://orcid.org/0000-0001-8818-8316)
- Ji‐Youn Han (ORCID: https://orcid.org/0000-0001-5033-0006)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5376-5109)
- Takayuki Asato (ORCID: https://orcid.org/0000-0003-1307-1505)
- Robert J. Fram (ORCID: https://orcid.org/0000-0001-7216-3130)
- Sanjay Popat (ORCID: https://orcid.org/0000-0003-2087-4963)
- Yuichiro Ohe
- James Chih‐Hsin Yang (ORCID: https://orcid.org/0000-0002-5586-5138)
- Angelo Delmonte (ORCID: https://orcid.org/0000-0001-9065-6123)
- Kentarou Kudou (ORCID: https://orcid.org/0000-0003-0125-6174)
- Florin Vranceanu
- Shunichi Sugawara (ORCID: https://orcid.org/0000-0002-3427-4558)
- Bradley Hupf
- D. Ross Camidge (ORCID: https://orcid.org/0000-0003-3430-3213)
- Hye Ryun Kim
Institutions
- Fujita Health University (JP)
- Yonsei University (KR)
- Samsung Medical Center (KR)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- National Cancer Center (KR)
- Royal Marsden Hospital (GB)
- National Taiwan University Hospital (TW)
- University of Colorado Cancer Center (US)
- Takeda (United States) (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Chungbuk National University Hospital (KR)
- Karl Landsteiner Society (AT)
- Sendai Kousei Hospital (JP)
- Takeda (Japan) (JP)
- Sungkyunkwan University (KR)
- University of Colorado Denver (US)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108424
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Takeda Oncology